BridgeMD
New treatment option for Human Papillomavirus Associated Carcinomas
Official title SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas
ClinicalTrials.gov ID: NCT06544720
What this study is testing
What is SCG142 TCR-T cells?
SCG142 TCR-T cells is an investigational medicine, being studied as a potential treatment for human papillomavirus associated carcinomas.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- A multicenter, open, single arm dose escalation and dose expansion phase I study to evaluate the safety, tolerability, and efficacy of SCG142 TCR-T cells in Subjects with advanced HPV associated carcinomas.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Greater than or equal to 18 years of age
- HPV associated carcinomas
- Patients must have at least one measurable lesion defined by RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 Key
You likely can't join if
- Active or uncontrollable infections or other active major medical illnesses of the cardiovascular, respiratory.
- Patients with active autoimmune diseases.
- Patient has a known active Hepatitis B or Hepatitis C.
- Other severe medical conditions that may limit subject\'s participation in this trial.
The study team makes the final eligibility decision.
Where it's taking place
- Qingdao, Shandong, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Qingdao, Shandong, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.